ARVO 2023: Managing myopia progression with low concentration atropine

Mark Bullimore, PhD, MCOptom, adjunct professor with the University of Houston College of Optometry, gives key highlights from his presentation on controling myopia progression with low concentration atrophy, which he presented during the 2023 Association for Research in Vision and Ophthalmology (ARVO) meeting in New Orleans.

Editor's note: This transcript has been lightly edited for clarity.

Mark Bullimore, PhD, MCOptom:

My name is Mark Bullimore. I'm an adjunct professor with the University of Houston College of Optometry, and I'm here at the ARVO meeting. I want to talk to you today about one of our presentations that concerns the control of myopia progression with low concentration atropine.

Specifically, we looked at the data from the LAMP (Low-Concentration Atropine for Myopia Progression ) study from Hong Kong, one of the most important studies of recent years. Now unfortunately, in the LAMP study, they only had control subjects on a placebo for the first year of a 3 year study.

But what we were able to do is to take those 1 year data and predict what the control population would have done over the 3 years using a 15% slowing per year. And from that, we're able to estimate the free efficacy of the different concentrations of atropine.

So I encourage you to look at the paper, and thank you for your attention.

Disclosure: Mark Bullimore is a consultant for Alcon Research, CooperVision, CorneaGen, EssilorLuxottica, Euclid Systems, Eyenovia, Genentech, Johnson & Johnson Vision, Lentechs, Novartis, Paragon Vision Sciences, and Vyluma.